Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Alaunos Therapeutics, Inc. (ZIOP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives"
07/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/12/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc.",
"Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Alaunos Therapeutics Reports First Quarter 2023 Financial Results"
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/04/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
04/03/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/30/2023 8-K Quarterly results
03/07/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results"
02/14/2023 SC 13G/A MSD Partners, L.P. reports a 7% stake in Alaunos Therapeutics, Inc.
02/14/2023 SC 13G/A DISCOVERY CAPITAL MANAGEMENT, LLC / CT reports a 6.7% stake in Alaunos Therapeutics, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 3.8% stake in Alaunos Therapeutics Inc.
01/20/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 8-K Quarterly results
01/04/2023 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/30/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/28/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
11/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Alaunos Therapeutics to Present Data Highlighting its hunTR ™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting"
09/30/2022 8-K Quarterly results
09/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference"
09/08/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/07/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy"
08/31/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/24/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy